ICI and Viral Sign a Form a Strategic Alliance

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

January 27, 2021

ICI and Viral Sign strategic alliance will allow both companies to supply advanced screening systems intended to help slow the spread of infectious disease, including COVID-19.

Under the terms of the partnership, ICI will be the exclusive supplier of thermal-camera hardware, including ICI’s flagship FMX400, to Viral Sign’s future installations.  ICI is the supplier of choice to Fortune 500 companies, and to agencies of the U.S. federal government.  ICI’s hardware, which has received 510(k) clearance from the FDA, is renowned for its high quality and market-leading accuracy.

By partnering with Viral Sign, ICI expands and strengthens its distribution footprint, and significantly increases its reach into additional sites of care. The partnership is particularly relevant to employers with significant operational and economic risk due to infectious disease, including senior living, healthcare, food processing, manufacturing, education, and hospitality.

Viral Sign’s proprietary software algorithms help to identify the presence of virus, including COVID-19, in individuals prior to the onset of symptoms. Early identification of the potential for a contagious virus helps to ensure a safe work environment for employees and a safe return of employees to their families at the end of the workday. Viral Sign leverages the power of infrared imaging and an advanced screening algorithm to produce a comprehensive thermal signature of the face.

In real-time, Viral Sign’s advanced screening algorithm assesses the thermal signature across regions of interest in the face to identify patterns consistent with early, presymptomatic influenza-like illness, including COVID-19. Viral Sign represents a significant advance in screening science relative to body temperature or symptom-focused screening platforms.

The ICI/Viral Sign partnership is the result of a shared commitment to helping employers create a “site safe” workplace for employees, customers, and guests.  Working together, ICI and Viral Sign will also continue to develop software platforms that equip their customers to acquire and report real-time, secure insights about workplace safety both on-site and across multiple installations.  These development efforts will enable the acceleration of insights into human health that can transform the use of thermal technology for healthcare and wellness applications.

Gary Strahan, the CEO of ICI commented: “Viral Sign is a true innovator in the use of thermal technology for improvements in public health.  We are proud to be their exclusive supplier, and we look forward to working with Viral Sign to co-develop innovative world-class solutions to public health problems.”

Barry Hix, the CEO of Viral Sign said: “ICI’s name is synonymous with best-in-class accuracy and reliability in thermal-screening technology.  The rich data generated by ICI cameras align perfectly with Viral Sign’s software algorithms, enhancing our ability to provide predictive insights into the health of individuals, workforces, and communities.  We look forward to rolling out our ICI-powered systems into our client base, and to working with ICI on additional technology development.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.